SavedAdd your journal

Journals / Güncel Retina Dergisi / 2018 / Cilt: 2 - Sayı: 2

New Developments and New Medicines in Treatment of Diabetic Retinopathy and Diabetic Macular Edema

Diyabetik Retinopati ve Diyabetik Maküla Ödemi Tedavisinde Yeni Gelişmeler ve Yeni İlaçlar

Nil İrem UÇGUN
Cenk ZEKİ FİKRET
Pages
185–188
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

New researches are ongoing about both pathways for diabetic retinopathy and macular edema therapy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The blood-retina barrier alteration is hallmark feature of diabetic retinopathy.
📊
Key Findings & Data:Vascular endothelial growth factor is an important vasopermeability factor that playing role in pathogenesis of blood retina barrier destruction.
💡
Conclusion & Impact:New researches are ongoing about both pathways for diabetic retinopathy and macular edema therapy
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The blood-retina barrier alteration is hallmark feature of diabetic retinopathy. Vascular endothelial growth factor is an important vasopermeability factor that playing role in pathogenesis of blood retina barrier destruction. Inflammation is the second pathology in diabetic retinopathy. New researches are ongoing about both pathways for diabetic retinopathy and macular edema therapy

Özet

Kan-retina bariyerindeki değişim diyabetik retinopatideki asıl patolojidir. Vasküler endotelyal büyüme faktörü kan-retina bariyerindeki hasar üzerine etkili bir vazopermeabilite faktörüdür. Enflamasyon diyabetik retinopatide ikinci önemli patolojidir. Diyabetik retinopati ve makula ödemi tedavisinde sıklıkla bu iki etkili mekanizmaya yönelik moleküller araştırılmaktadır

🔖

Cite This Article

UÇGUN, N. İ., FİKRET, C. Z. (2018). New Developments and New Medicines in Treatment of Diabetic Retinopathy and Diabetic Macular Edema. Güncel Retina Dergisi, Cilt: 2 - Sayı: 2, 185–188. https://ajindex.com/articles/214867

References (11)

  1. Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase 1/2 study. Am J Ophthalmol. 2013
  2. 155(4):697-704 2. Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, et al. Safety and efficacy of conbercept in neovascular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 2014
  3. 121(9):1740-1747 3. Xu Y, Rong A, Xu W, Niu Y, Wang Z. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. BMC Ophthalmology 2017
  4. 17(1):158 4. Kauper K, McGroven C, Sherman S, Heatherton P, Rapoza R, Stabila P, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis. Sci. 2012
  5. 53(12):7484-7491 5. Pearce W, Hsu J, Yeh S. Advaces in drug delivery to the posterior segment. Curr Opin Ophthalmol. 2015
  6. 26(3):233-239 6. Das A, McGuire PG, Monickaraj F. Novel pharmacotherapies in diabetic retinopathy: Current status and what’s in the horizon? Indian Journal of ophthalmology 2016
  7. 64(1):4-13 7. Stewart M.W. Investigational Medications. Stewart M.W. In: Diabetic Retinopathy Current pharmacologic treatment and emerging strategies. USA, Adis,2017
  8. 238 8. Humayun M, Santos A, Altamirano JC, Ribeiro R, Gonzalez R, de la Rosa A et al. Implantable micropump for drug delivery in patients with diabetic macular edema. Transl Vis Sci Technol. 2014
  9. 3(6):5 eCollection 2014 9. Clinical Trials.gov Identifier: NCT02307682 Last update posted: 6 July,2017 10. Chhablani J, Narayanan R, Mathai A, Yogi R, Stewart M. Short- term safety profile of intravitreal ziv-aflibercept. Retina. 2016
  10. 36(6):1126-1131 11. Rosberger DF. Diabetic retinopathy. Current concepts and emerging theraphy. Endocrinol Metab Clin North Am. 2013
  11. 745 12. Bar-Or D, Orlando A, Singer M, danazol study group. Potential benefical efect of low-dose danazol in combination with renin-angiotensin system inhibitors in diabetic macular edema. Acta Ophthalmologica 2016 DOI 10.1111/ aos.13318 13. Clinical Trials.gov Identifier: NCT02002403 Last update posted: 6. December. 2013 14. Tanito M, Hara K, Takai Y, Matsuoka Y, Nishimura N, Jansook P, et al. Topikal dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci. 2